Chris Whitehouse, a political consultant and expert on medical technology policy and regulation at Whitehouse Communications, and advisor to MedTech suppliers, reports on recent developments at NHS Supply Chain and their potential implications for suppliers, the NHS, patients, and the wider MedTech sector.
Emerging reports suggest that NHS Supply Chain (NHSSC) is planning to move future framework awards towards a more selective model, so reducing access for clinicians to the wider range of MedTech products that might be most appropriate for their patients, whilst damaging plurality and diversity of supply, and threatening future innovation, particularly by start-ups and smaller and medium-sized enterprise.
Instead of broader, multi-supplier frameworks, it seems NHSSC intends that awards will focus on a smaller number of top-ranked suppliers. The shift reflects apparent concern in NHSSC that large frameworks have diluted commercial discipline and struggled to deliver consistent value to the NHS.
By narrowing the field, NHSSC aims to sharpen competition and promote a procurement environment where suppliers are rewarded not for simply securing a place on a list, but also for demonstrably “delivering value”.
While this shift has the potential to drive greater value and strengthen overall quality, it also carries significant implications for sector stakeholders, particularly suppliers and the wider MedTech sector.
A more selective model raises the competitive stakes, with framework places increasingly dependent on demonstrable operational performance and clear evidence of value. For SMEs and newer entrants, barriers to entry may be raised even higher – not due to product quality, but because of limited track record or resources to meet the evidence requirements.
Innovation is also particularly exposed. Prioritising proven performance can strengthen consistency and quality, but it may also disadvantage new technologies that have yet to build extensive NHS evidence. Unless evaluation criteria explicitly accommodate emerging solutions, this new approach may slow the adoption of innovations that could deliver long-term benefits to patients and the NHS, so proving counter-productive.
For the NHS and patients, the consequences are similarly nuanced. While a smaller supplier pool could enhance reliability and quality assurance, reduced market diversity may limit clinical choice and access to specialist or niche products, raising concerns about the flexibility required for truly patient-centred care. Balancing consistency and choice will become increasingly important.
Overall, a move towards more selective frameworks would mark a significant transition in NHS procurement strategy. It would have the potential to enhance efficiency and strengthen accountability but also carries risks around innovation and market diversity.
The ultimate impact will depend on how transparently NHS Supply Chain applies its principles, how flexibly it accommodates new technologies, and how effectively it engages stakeholders, including suppliers, clinicians, and trusts, throughout implementation.
Whilst past NHSSC performance in these areas is no guarantee of the future, suppliers of MedTech devices and consumables might feel they have reasonable grounds for concern. Indeed, such direction of NHSSC travel as that now emerging risks undermining not only the wider introduction of value-based procurement to which Ministers are committed in “early 2026”, but also the Government’s commitment to patient-centred care.
The Author used AI in preparing this article. Comments upon or questions about this article can be addressed to chris.whitehouse@whitehousecomms.com.
